Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma

Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Sugino, Yuichi [verfasserIn] Yamakado, Koichiro Yamanaka, Takashi Fujimori, Masashi Nakatsuka, Atsuhiro Takaki, Haruyuki Takei, Yoshiyuki Sakuma, Hajime Isaji, Shuji

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2017

Schlagwörter:	Intermediate stage Curative treatment Treatment allocation Prognosis

Anmerkung:	© Japan Radiological Society 2017

Übergeordnetes Werk:	Enthalten in: Radiation medicine - Tokyo : Springer, 1999, 35(2017), 5 vom: 29. März, Seite 254-261
Übergeordnetes Werk:	volume:35 ; year:2017 ; number:5 ; day:29 ; month:03 ; pages:254-261

Links:	Volltext

DOI / URN:	10.1007/s11604-017-0628-9

Katalog-ID:	SPR02103950X

Internformat


LEADER	01000caa a22002652 4500
001	SPR02103950X
003	DE-627
005	20230519224820.0
007	cr uuu---uuuuu
008	201006s2017 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11604-017-0628-9 \|2 doi
035			\|a (DE-627)SPR02103950X
035			\|a (SPR)s11604-017-0628-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Sugino, Yuichi \|e verfasserin \|4 aut
245	1	0	\|a Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Japan Radiological Society 2017
520			\|a Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs.
650		4	\|a Intermediate stage \|7 (dpeaa)DE-He213
650		4	\|a Curative treatment \|7 (dpeaa)DE-He213
650		4	\|a Treatment allocation \|7 (dpeaa)DE-He213
650		4	\|a Prognosis \|7 (dpeaa)DE-He213
700	1		\|a Yamakado, Koichiro \|4 aut
700	1		\|a Yamanaka, Takashi \|4 aut
700	1		\|a Fujimori, Masashi \|4 aut
700	1		\|a Nakatsuka, Atsuhiro \|4 aut
700	1		\|a Takaki, Haruyuki \|4 aut
700	1		\|a Takei, Yoshiyuki \|4 aut
700	1		\|a Sakuma, Hajime \|4 aut
700	1		\|a Isaji, Shuji \|4 aut
773	0	8	\|i Enthalten in \|t Radiation medicine \|d Tokyo : Springer, 1999 \|g 35(2017), 5 vom: 29. März, Seite 254-261 \|w (DE-627)368312305 \|w (DE-600)2117284-5 \|x 1862-5274 \|7 nnns
773	1	8	\|g volume:35 \|g year:2017 \|g number:5 \|g day:29 \|g month:03 \|g pages:254-261
856	4	0	\|u https://dx.doi.org/10.1007/s11604-017-0628-9 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 35 \|j 2017 \|e 5 \|b 29 \|c 03 \|h 254-261

Indexfelder

author_variant	y s ys k y ky t y ty m f mf a n an h t ht y t yt h s hs s i si
matchkey_str	article:18625274:2017----::oefuaieramniptetwtitreitsaee
hierarchy_sort_str	2017
publishDate	2017
allfields	10.1007/s11604-017-0628-9 doi (DE-627)SPR02103950X (SPR)s11604-017-0628-9-e DE-627 ger DE-627 rakwb eng Sugino, Yuichi verfasserin aut Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Japan Radiological Society 2017 Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. Intermediate stage (dpeaa)DE-He213 Curative treatment (dpeaa)DE-He213 Treatment allocation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Yamakado, Koichiro aut Yamanaka, Takashi aut Fujimori, Masashi aut Nakatsuka, Atsuhiro aut Takaki, Haruyuki aut Takei, Yoshiyuki aut Sakuma, Hajime aut Isaji, Shuji aut Enthalten in Radiation medicine Tokyo : Springer, 1999 35(2017), 5 vom: 29. März, Seite 254-261 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:35 year:2017 number:5 day:29 month:03 pages:254-261 https://dx.doi.org/10.1007/s11604-017-0628-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 35 2017 5 29 03 254-261
spelling	10.1007/s11604-017-0628-9 doi (DE-627)SPR02103950X (SPR)s11604-017-0628-9-e DE-627 ger DE-627 rakwb eng Sugino, Yuichi verfasserin aut Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Japan Radiological Society 2017 Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. Intermediate stage (dpeaa)DE-He213 Curative treatment (dpeaa)DE-He213 Treatment allocation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Yamakado, Koichiro aut Yamanaka, Takashi aut Fujimori, Masashi aut Nakatsuka, Atsuhiro aut Takaki, Haruyuki aut Takei, Yoshiyuki aut Sakuma, Hajime aut Isaji, Shuji aut Enthalten in Radiation medicine Tokyo : Springer, 1999 35(2017), 5 vom: 29. März, Seite 254-261 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:35 year:2017 number:5 day:29 month:03 pages:254-261 https://dx.doi.org/10.1007/s11604-017-0628-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 35 2017 5 29 03 254-261
allfields_unstemmed	10.1007/s11604-017-0628-9 doi (DE-627)SPR02103950X (SPR)s11604-017-0628-9-e DE-627 ger DE-627 rakwb eng Sugino, Yuichi verfasserin aut Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Japan Radiological Society 2017 Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. Intermediate stage (dpeaa)DE-He213 Curative treatment (dpeaa)DE-He213 Treatment allocation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Yamakado, Koichiro aut Yamanaka, Takashi aut Fujimori, Masashi aut Nakatsuka, Atsuhiro aut Takaki, Haruyuki aut Takei, Yoshiyuki aut Sakuma, Hajime aut Isaji, Shuji aut Enthalten in Radiation medicine Tokyo : Springer, 1999 35(2017), 5 vom: 29. März, Seite 254-261 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:35 year:2017 number:5 day:29 month:03 pages:254-261 https://dx.doi.org/10.1007/s11604-017-0628-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 35 2017 5 29 03 254-261
allfieldsGer	10.1007/s11604-017-0628-9 doi (DE-627)SPR02103950X (SPR)s11604-017-0628-9-e DE-627 ger DE-627 rakwb eng Sugino, Yuichi verfasserin aut Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Japan Radiological Society 2017 Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. Intermediate stage (dpeaa)DE-He213 Curative treatment (dpeaa)DE-He213 Treatment allocation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Yamakado, Koichiro aut Yamanaka, Takashi aut Fujimori, Masashi aut Nakatsuka, Atsuhiro aut Takaki, Haruyuki aut Takei, Yoshiyuki aut Sakuma, Hajime aut Isaji, Shuji aut Enthalten in Radiation medicine Tokyo : Springer, 1999 35(2017), 5 vom: 29. März, Seite 254-261 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:35 year:2017 number:5 day:29 month:03 pages:254-261 https://dx.doi.org/10.1007/s11604-017-0628-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 35 2017 5 29 03 254-261
allfieldsSound	10.1007/s11604-017-0628-9 doi (DE-627)SPR02103950X (SPR)s11604-017-0628-9-e DE-627 ger DE-627 rakwb eng Sugino, Yuichi verfasserin aut Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Japan Radiological Society 2017 Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. Intermediate stage (dpeaa)DE-He213 Curative treatment (dpeaa)DE-He213 Treatment allocation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Yamakado, Koichiro aut Yamanaka, Takashi aut Fujimori, Masashi aut Nakatsuka, Atsuhiro aut Takaki, Haruyuki aut Takei, Yoshiyuki aut Sakuma, Hajime aut Isaji, Shuji aut Enthalten in Radiation medicine Tokyo : Springer, 1999 35(2017), 5 vom: 29. März, Seite 254-261 (DE-627)368312305 (DE-600)2117284-5 1862-5274 nnns volume:35 year:2017 number:5 day:29 month:03 pages:254-261 https://dx.doi.org/10.1007/s11604-017-0628-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 35 2017 5 29 03 254-261
language	English
source	Enthalten in Radiation medicine 35(2017), 5 vom: 29. März, Seite 254-261 volume:35 year:2017 number:5 day:29 month:03 pages:254-261
sourceStr	Enthalten in Radiation medicine 35(2017), 5 vom: 29. März, Seite 254-261 volume:35 year:2017 number:5 day:29 month:03 pages:254-261
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Intermediate stage Curative treatment Treatment allocation Prognosis
isfreeaccess_bool	false
container_title	Radiation medicine
authorswithroles_txt_mv	Sugino, Yuichi @@aut@@ Yamakado, Koichiro @@aut@@ Yamanaka, Takashi @@aut@@ Fujimori, Masashi @@aut@@ Nakatsuka, Atsuhiro @@aut@@ Takaki, Haruyuki @@aut@@ Takei, Yoshiyuki @@aut@@ Sakuma, Hajime @@aut@@ Isaji, Shuji @@aut@@
publishDateDaySort_date	2017-03-29T00:00:00Z
hierarchy_top_id	368312305
id	SPR02103950X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR02103950X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11604-017-0628-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR02103950X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11604-017-0628-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sugino, Yuichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Japan Radiological Society 2017</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intermediate stage</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Curative treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment allocation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamakado, Koichiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamanaka, Takashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujimori, Masashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakatsuka, Atsuhiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takaki, Haruyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takei, Yoshiyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sakuma, Hajime</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Isaji, Shuji</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Radiation medicine</subfield><subfield code="d">Tokyo : Springer, 1999</subfield><subfield code="g">35(2017), 5 vom: 29. März, Seite 254-261</subfield><subfield code="w">(DE-627)368312305</subfield><subfield code="w">(DE-600)2117284-5</subfield><subfield code="x">1862-5274</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:5</subfield><subfield code="g">day:29</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:254-261</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11604-017-0628-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2017</subfield><subfield code="e">5</subfield><subfield code="b">29</subfield><subfield code="c">03</subfield><subfield code="h">254-261</subfield></datafield></record></collection>
author	Sugino, Yuichi
spellingShingle	Sugino, Yuichi misc Intermediate stage misc Curative treatment misc Treatment allocation misc Prognosis Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
authorStr	Sugino, Yuichi
ppnlink_with_tag_str_mv	@@773@@(DE-627)368312305
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1862-5274
topic_title	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma Intermediate stage (dpeaa)DE-He213 Curative treatment (dpeaa)DE-He213 Treatment allocation (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213
topic	misc Intermediate stage misc Curative treatment misc Treatment allocation misc Prognosis
topic_unstemmed	misc Intermediate stage misc Curative treatment misc Treatment allocation misc Prognosis
topic_browse	misc Intermediate stage misc Curative treatment misc Treatment allocation misc Prognosis
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Radiation medicine
hierarchy_parent_id	368312305
hierarchy_top_title	Radiation medicine
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)368312305 (DE-600)2117284-5
title	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
ctrlnum	(DE-627)SPR02103950X (SPR)s11604-017-0628-9-e
title_full	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
author_sort	Sugino, Yuichi
journal	Radiation medicine
journalStr	Radiation medicine
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
container_start_page	254
author_browse	Sugino, Yuichi Yamakado, Koichiro Yamanaka, Takashi Fujimori, Masashi Nakatsuka, Atsuhiro Takaki, Haruyuki Takei, Yoshiyuki Sakuma, Hajime Isaji, Shuji
container_volume	35
format_se	Elektronische Aufsätze
author-letter	Sugino, Yuichi
doi_str_mv	10.1007/s11604-017-0628-9
title_sort	role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
title_auth	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
abstract	Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. © Japan Radiological Society 2017
abstractGer	Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. © Japan Radiological Society 2017
abstract_unstemmed	Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs. © Japan Radiological Society 2017
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_138 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	5
title_short	Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma
url	https://dx.doi.org/10.1007/s11604-017-0628-9
remote_bool	true
author2	Yamakado, Koichiro Yamanaka, Takashi Fujimori, Masashi Nakatsuka, Atsuhiro Takaki, Haruyuki Takei, Yoshiyuki Sakuma, Hajime Isaji, Shuji
author2Str	Yamakado, Koichiro Yamanaka, Takashi Fujimori, Masashi Nakatsuka, Atsuhiro Takaki, Haruyuki Takei, Yoshiyuki Sakuma, Hajime Isaji, Shuji
ppnlink	368312305
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s11604-017-0628-9
up_date	2024-07-03T19:55:08.592Z
_version_	1803589002035462144
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR02103950X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519224820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2017 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11604-017-0628-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR02103950X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11604-017-0628-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sugino, Yuichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Japan Radiological Society 2017</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose To retrospectively evaluate the role of curative treatment in patients with intermediate-stage hepatocellular carcinomas (HCCs), and to identify the subgroup having benefit from curative treatment. Methods From April 2000 to December 2014, 100 patients with intermediate-stage HCCs underwent either curative treatment (hepatectomy: n = 23, radiofrequency ablation (RFA); n = 29, both: n = 4) or transarterial chemoembolization (TACE): n = 44) as initial treatments for HCCs. Overall survival, influence of treatment allocation on prognosis, and factors affecting treatment allocation were evaluated. Results The 5-year survival rate was 59.2% [95% confidence interval (CI) 51.6–66.8%] in the curative group, and 25.1% (95% CI 11.5–38.7%) in the TACE group. Treatment allocation was the only significant prognostic factor (p = 0.014, hazard ratio: 0.382, 95% CI 0.177–0.821). The curative group consisted of more patients with Child-Pugh A (p = 0.0016) than the TACE group, a tumor number of 3 or fewer (p < 0.0001), a unilobar tumor location (p = 0.02), within 4 of 7 cm criterion (p = 0.001), and within up-to-7 criterion (p = 0.04). Child-Pugh A, within the 4 of 7 cm criterion, and a unilobar tumor location were significantly linked with treatment allocation in multivariate analysis. Conclusions Curative treatment can prolong survival in selected patients with intermediate-stage HCCs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Intermediate stage</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Curative treatment</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment allocation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamakado, Koichiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yamanaka, Takashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujimori, Masashi</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nakatsuka, Atsuhiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takaki, Haruyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takei, Yoshiyuki</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sakuma, Hajime</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Isaji, Shuji</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Radiation medicine</subfield><subfield code="d">Tokyo : Springer, 1999</subfield><subfield code="g">35(2017), 5 vom: 29. März, Seite 254-261</subfield><subfield code="w">(DE-627)368312305</subfield><subfield code="w">(DE-600)2117284-5</subfield><subfield code="x">1862-5274</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:35</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:5</subfield><subfield code="g">day:29</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:254-261</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11604-017-0628-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">35</subfield><subfield code="j">2017</subfield><subfield code="e">5</subfield><subfield code="b">29</subfield><subfield code="c">03</subfield><subfield code="h">254-261</subfield></datafield></record></collection>
score	7.401046

Nicht das Richtige dabei?

Schreiben Sie uns!

Role of curative treatment in patients with intermediate-stage hepatocellular carcinoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?